Ximi Elga


GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.

Author: Donos Zulushakar
Country: Monaco
Language: English (Spanish)
Genre: Technology
Published (Last): 22 March 2012
Pages: 198
PDF File Size: 7.39 Mb
ePub File Size: 17.8 Mb
ISBN: 363-8-65820-189-3
Downloads: 59172
Price: Free* [*Free Regsitration Required]
Uploader: Fekree

Use with extreme caution in patients with an increased risk of hemorrhage e.

Mylan Worldwide

Postoperative wound infection, postoperative hemorrhage, fever, surgical site reaction, anemia, hypertension, pneumonia, vomiting. Several antithrombotic agents e. Postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: N Engl J Med.

Patients undergoing hip-fracture, hip- or knee-replacement surgery: Constipation, headache, insomnia, fever, nausea, urinary tract infection, coughing.

History of serious hypersensitivity reaction e. Available for Android and iOS perscribing. Usual duration of therapy is 5—9 days, although up to 10 days has been studied.

If coadministration is essential, monitor patients closely Anticoagulant effects may persist for 2—4 days following discontinuance of therapy in patients with normal renal function i. In general, pharmacologic thromboprophylaxis is recommended only in such patients considered to be at high risk of venous thromboembolism.


We comply with the HONcode standard for trustworthy health information – verify here. Used for extended prophylaxis i. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices.

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: Optimal timing between administration of fondaparinux and neuraxial procedures not known. In healthy adults, distributes mainly in blood and only to a minor extent in extravascular fluid.

Importance of discontinuing fondaparinux and onformation contacting a clinician if a serious allergic reaction e.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: Subscribe to receive email notifications whenever new articles are published.

Prevention of VTE in orthopedic surgery patients: Bounameaux, H, Perneger T. Prevention of VTE in nonorthopedic surgical patients: Dosages for fondaparinux sodium and heparin, heparinoids, or LMWHs cannot be used interchangeably on a unit-for-unit or mg-for-mg basis 1 as they differ in the manufacturing process, anti-factor Xa and antithrombin activity, and dosage. Active major bleeding, bacterial endocarditis, or thrombocytopenia associated with a positive in vitro test for antiplatelet antibody HIT in the presence of the drug.


Evaluate the possibility of an underlying bleeding disorder before initiation of treatment. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. Anticoagulation results from rapid inhibition of factor Xa by antithrombin III bound to fondaparinux about fold greater than innate activity.

Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.

Do not administer earlier than 6—8 hours after surgery because of increased risk of major bleeding.

Arixtra Monograph for Professionals –

Am J Health-Syst Pharm. Prevention of postoperative DVT and PE in patients undergoing hip-fracture, hip-replacement, or knee-replacement surgery. Increased risk of hemorrhage; closely monitor for signs and symptoms of bleeding.